Agendia Achieves CE-IVDR Certification
Agendia Achieves CE-IVDR Certification for its MammaPrint and BluePrint Breast Cancer Assays
Read More
Agendia Announces JCO Publication on MammaPrint Utility in NRG/NSABP B-42 Trial
MammaPrint 70-gene Assay Evaluated in the NRG Oncology/NSABP B-42 Trial
Read More
MammaPrint High 2 tumors exhibit heightened immune active state
Elucidating the immune active state of HR+HER2- MammaPrint High 2 early breast cancer
Read More
MammaPrint & 3-year outcome of CT with/without anthracycline-ASCO 2024
Association of MammaPrint index and 3-year outcome of patients in the FLEX Registry trial with HR+HER2- early-stage breast cancer treated with chemotherapy with or without anthracycline
Read More
Agendia to Unveil Robust Suite of Data at 2024 ASCO
Agendia to Unveil Robust Suite of Data at 2024 ASCO to Further Advance Breast Cancer Care
Read More
German Gynecological Oncology Group (AGO) includes BluePrint® in Guidelines
German Gynecological Oncology Group (AGO) Recognizes BluePrint® in Breast Cancer Guidelines
Read More
Agendia Announces New I-SPY2 Data Showcasing Ability of New Signature ImPrintTN
Agendia Announces New Data from I-SPY 2 Showcasing Ability of New Signature ImPrintTN to Predict Immunotherapy Response in Patients with Triple Negative Breast Cancer
Read More
Agendia Presents Data from FLEX Study at Miami Breast 2024
Agendia Presents Data at Miami Breast 2024 Demonstrating MammaPrint® + BluePrint®’s Ability to Further Stratify Tumor Categories in Hormone-Positive Breast Cancer, Highlighting Response to Different Chemotherapy Regimens
Read MoreAgendia Reports First Patient Enrolled in DEBRA Trial Using MammaPrint
MammaPrint 70-gene signature to aid in evaluation of de-escalation of radiation therapy in Stage I, Hormone Sensitive, HER2-Negative breast cancer
Read More
Agendia® Collaborates with National Cancer Institute, SWOG Cancer Research Network for Phase III Trial; Led by University of Michigan’s Dr. Erin Cobain GalleryAgendia® Collaborates with National Cancer Institute, SWOG Cancer Research Network for Phase III Trial; Led by University of Michigan’s Dr. Erin Cobain
Agendia® Collaborates with National Cancer Institute, SWOG Cancer Research Network for Phase III Trial; Led by University of Michigan’s Dr. Erin Cobain
SWOG S2206 will use MammaPrint® breast cancer recurrence test to examine response to immunotherapy in women with high-risk HR+ breast cancer.
Read More
